N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法,重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。
N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法,重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.